An Introduction to Vaccines
Vaccines have substantially reduced morbidity and mortality from infectious diseases in the
developed world. Many vaccines, including those for measles and some influenza vaccines,
use live attenuated viruses. The COVID-19 pandemic has led to unprecedented rates of
vaccine development, raising hopes that other vaccines might be made on a comparable
timescale in the future. In particular, it has established the clinical utility of mRNA vaccines,
which have demonstrated high potency, capacity for rapid development and potential for
low-cost manufacture and safe administration. In addition, other approaches, including
nucleic acid-based vaccines, recombinant DNA platforms, virus-like particle (VLP) based
vaccines, non-replicating viral vectors, recombinant nanoparticles and peptide vaccines in
active clinical development.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Louis Picker, HIVR4P 2021: CMV-vector vaccines for HIV Prevention
It was a pleasure to speak with Louis Picker (VGTI-Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR, USA) to discuss his work in CMV-vector vaccines for HIV prevention. The abstract entitled: ‘CMV-vectored vaccines for HIV prevention’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021. Questions: Could you […]
Tomáš Hanke, HIVR4P 2021: T cell responses in HIV to inform vaccine development (Part 2)
It was a pleasure to speak with Tomáš Hanke (University of Oxford, Oxford, UK) to discuss his recent work in T cell responses in HIV to inform vaccine development. His abstract entitled: ‘Refocusing T cell responses with therapeutic vaccination strategies’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021. Part 1 of […]
Tomáš Hanke, HIVR4P 2021: T cell Vaccines for HIV-1 Infection (Part 1)
We caught up with Tomáš Hanke (University of Oxford, Oxford, UK) to discuss T-cell vaccine strategies for the treatment of people with HIV-1 infection. His abstract entitled: ‘Refocusing T cell responses with therapeutic vaccination strategies’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021. Part 2 of our discussion can be viewed […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!